Engraftment potential of dermal fibroblasts following in vivo myogenic conversion in immunocompetent dystrophic skeletal muscle

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14025-

  Muir, Lindsey A ^a,c   Nguyen, Quynh G ^b   Hauschka, Stephen D ^b   Chamberlain, Jeffrey S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84961127382     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.25     Document Type: Article

References (50)

1. Batchelor, CL and Winder, SJ (2006). Sparks, signals and shock absorbers: how dystrophin loss causes muscular dystrophy. Trends Cell Biol 16: 198-205.
2. Emery, AE and Muntoni, F (2003). Duchenne Muscular Dystrophy, 3rd edn, Oxford University Press: Oxford.
3. Muir, LA and Chamberlain, JS (2009). Emerging strategies for cell and gene therapy of the muscular dystrophies. Expert Rev Mol Med 11: e18.
4. Bertoni, C (2014). Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells. Front Physiol 5: 148.
5. Skuk, D, Paradis, M, Goulet, M and Tremblay, JP (2007). Ischemic central necrosis in pockets of transplanted myoblasts in nonhuman primates: implications for cell-transplantation strategies. Transplantation 84: 1307-1315.
6. Blau, HM, Webster, C and Pavlath, GK (1983). Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 80: 4856-4860.
7. Yablonka-Reuveni, Z and Anderson, JE (2006). Satellite cells from dystrophic (mdx) mice display accelerated differentiation in primary cultures and in isolated myofibers. Dev Dyn 235: 203-212.
8. Vierbuchen, T and Wernig, M (2012). Molecular roadblocks for cellular reprogramming. Mol Cell 47: 827-838.
9. Lortal, B, Gross, F, Peron, JM, Pénary, M, Berg, D, Hennebelle, I et al. (2009). Preclinical study of an ex vivo gene therapy protocol for hepatocarcinoma. Cancer Gene Ther 16: 329-337.
10. van den Bogaerdt, AJ, van Zuijlen, P P, van Galen, M, Lamme, EN and Middelkoop, E (2002). The suitability of cells from different tissues for use in tissue-engineered skin substitutes. A rch Dermatol Res 294: 135-142.
11. Davis, RL, Weintraub, H and Lassar, AB (1987). Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51: 987-1000.
12. Gibson, AJ, Karasinski, J, Relvas, J, Moss, J, Sherratt, TG, Strong, PN et al. (1995). Dermal fibroblasts convert to a myogenic lineage in mdx mouse muscle. J Cell Sci 108 (Pt 1): 207-214.
13. Lattanzi, L, Salvatori, G, Coletta, M, Sonnino, C, Cusella De Angelis, MG, Gioglio, L et al. (1998). High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J Clin Invest 101: 2119-2128.
14. Huard, C, Moisset, PA, Dicaire, A, Merly, F, Tardif, F, Asselin, I et al. (1998). Transplantation of dermal fibroblasts expressing MyoD1 in mouse muscles. Biochem Biophys Res Commun 248: 648-654.
15. Crescenzi, M, Fleming, T P, Lassar, AB, Weintraub, H and Aaronson, SA (1990). MyoD induces growth arrest independent of differentiation in normal and transformed cells. Proc Natl Acad Sci USA 87: 8442-8446.
16. Del Bo, R, Torrente, Y, Corti, S, D'Angelo, MG, Comi, GP, Fagiolari, G et al. (2001). In vitro and in vivo tetracycline-controlled myogenic conversion of NIH-3T3 cells: evidence of programmed cell death after muscle cell transplantation. Cell Transplant 10: 209-221.
17. Hollenberg, SM, Cheng, PF and Weintraub, H (1993). Use of a conditional MyoD transcription factor in studies of MyoD trans-activation and muscle determination. Proc Natl Acad Sci USA 90: 8028-8032.
18. Danielian, PS, White, R, Hoare, SA, Fawell, SE and Parker, MG (1993). Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 7: 232-240.
19. Kimura, E, Han, JJ, Li, S, Fall, B, Ra, J, Haraguchi, M et al. (2008). Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Hum Mol Genet 17: 2507-2517.
20. Harper, SQ, Hauser, MA, DelloRusso, C, Duan, D, Crawford, RW, Phelps, SF et al. (2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8: 253-261.
21. Banks, GB, Gregorevic, P, Allen, JM, Finn, EE and Chamberlain, JS (2007). Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Hum Mol Genet 16: 2105-2113.
22. Li, S, Kimura, E, Ng, R, Fall, BM, Meuse, L, Reyes, M et al. (2006). A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum Mol Genet 15: 1610-1622.
23. Thayer, MJ, Tapscott, SJ, Davis, RL, Wright, WE, Lassar, AB and Weintraub, H (1989). Positive autoregulation of the myogenic determination gene MyoD1. Cell 58: 241-248.
24. Clegg, CH and Hauschka, SD (1987). Heterokaryon analysis of muscle differentiation: regulation of the postmitotic state. J Cell Biol 105: 937-947.
25. Salvatori, G, Lattanzi, L, Coletta, M, Aguanno, S, Vivarelli, E, Kelly, R et al. (1995). Myogenic conversion of mammalian fibroblasts induced by differentiating muscle cells. J Cell Sci 108 (Pt 8): 2733-2739.
26. Pomerantz, JH, Mukherjee, S, Palermo, AT and Blau, HM (2009). Reprogramming to a muscle fate by fusion recapitulates differentiation. J Cell Sci 122(Pt 7): 1045-1053.
27. Vidal, B, Serrano, AL, Tjwa, M, Suelves, M, Ardite, E, De Mori, R et al. (2008). Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev 22: 1747-1752.
28. Serrano, AL and Muñoz-Cánoves, P (2010). Regulation and dysregulation of fibrosis in skeletal muscle. Exp Cell Res 316: 3050-3058.
29. Hartigan-O'Connor, D, Kirk, CJ, Crawford, R, Mulé, JJ and Chamberlain, JS (2001). Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther 4: 525-533.
30. Harris, JB (2003). Myotoxic phospholipases A2 and the regeneration of skeletal muscles. Toxicon 42: 933-945.
31. Morgan, JE, Hoffman, EP and Partridge, TA (1990). Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. J Cell Biol 111(6 Pt 1): 2437-2449.
32. Gonçalves, MA, Swildens, J, Holkers, M, Narain, A, van Nierop, G P, van de Watering, MJ et al. (2008). Genetic complementation of human muscle cells via directed stem cell fusion. Mol Ther 16: 741-748.
33. Darabi, R, Arpke, RW, Irion, S, Dimos, JT, Grskovic, M, Kyba, M et al. (2012). Human ES-and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 10: 610-619.
34. Robinton, DA and Daley, GQ (2012). The promise of induced pluripotent stem cells in research and therapy. Nature 481: 295-305.
35. Seed, J and Hauschka, SD (1988). Clonal analysis of vertebrate myogenesis. VIII. Fibroblasts growth factor (FGF)-dependent and FGF-independent muscle colony types during chick wing development. Dev Biol 128: 40-49.
36. Tortorella, LL, Milasincic, DJ and Pilch, PF (2001). Critical proliferation-independent window for basic fibroblast growth factor repression of myogenesis via the p42/p44 MAPK signaling pathway. J Biol Chem 276: 13709-13717.
37. Périé, S, Trollet, C, Mouly, V, Vanneaux, V, Mamchaoui, K, Bouazza, B et al. (2014). Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I/IIa clinical study. Mol Ther 22: 219-225.
38. Skuk, D, Goulet, M, Roy, B, Piette, V, Côté, CH, Chapdelaine, P et al. (2007). First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord 17: 38-46.
39. Phelps, SF, Hauser, MA, Cole, NM, Rafael, JA, Hinkle, RT, Faulkner, JA et al. (1995). Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 4: 1251-1258.
40. Chamberlain, JS (1997). Dystrophin levels required for genetic correction of Duchenne muscular dystrophy. Basic Appl Myol 7: 251-255.
41. Blaveri, K, Heslop, L, Yu, DS, Rosenblatt, JD, Gross, JG, Partridge, TA et al. (1999). Patterns of repair of dystrophic mouse muscle: studies on isolated fibers. Dev Dyn 216: 244-256.
42. Lovering, RM, Michaelson, L and Ward, CW (2009). Malformed mdx myofibers have normal cytoskeletal architecture yet altered EC coupling and stress-induced Ca2+ signaling. Am J Physiol Cell Physiol 297: C571-C580.
43. Sharp, PS, Bye-a-Jee, H and Wells, DJ (2011). Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther 19: 165-171.
44. Lovering, RM, McMillan, AB and Gullapalli, RP (2009). Location of myofiber damage in skeletal muscle after lengthening contractions. Muscle Nerve 40: 589-594.
45. Tapscott, SJ (2005). The circuitry of a master switch: Myod and the regulation of skeletal muscle gene transcription. Development 132: 2685-2695.
46. Lapid, O, van Wingerden, JJ and Perlemuter, L (2013). Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review. J Pediatr Endocrinol Metab 26: 803-807.
47. Li, S, Kimura, E, Fall, BM, Reyes, M, Angello, JC, Welikson, R et al. (2005). Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Ther 12: 1099-1108.
48. Lichti, U, Anders, J and Yuspa, SH (2008). Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice. Nat Protoc 3: 799-810.
49. Linkhart, TA, Clegg, CH and Hauschka, SD (1980). Control of mouse myoblast commitment to terminal differentiation by mitogens. J Supramol Struct 14: 483-498.
50. Chapman, VM, Miller, DR, Armstrong, D and Caskey, CT (1989). Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci USA 86: 1292-1296.